WO2017093844A1 - Conjugués anticorps-médicaments anti-her2 spécifiques de sites - Google Patents

Conjugués anticorps-médicaments anti-her2 spécifiques de sites Download PDF

Info

Publication number
WO2017093844A1
WO2017093844A1 PCT/IB2016/057017 IB2016057017W WO2017093844A1 WO 2017093844 A1 WO2017093844 A1 WO 2017093844A1 IB 2016057017 W IB2016057017 W IB 2016057017W WO 2017093844 A1 WO2017093844 A1 WO 2017093844A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
heavy chain
light chain
cancer
constant region
Prior art date
Application number
PCT/IB2016/057017
Other languages
English (en)
Inventor
Dangshe Ma
JR. Frank LOGANZO
Kimberly Ann Marquette
Edmund Idris Graziani
Puja Sapra
Pavel Strop
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57485830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017093844(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2016363373A priority Critical patent/AU2016363373A1/en
Priority to KR1020207030005A priority patent/KR102312149B1/ko
Priority to RU2018119683A priority patent/RU2745565C2/ru
Priority to CN201680072749.4A priority patent/CN108473591B/zh
Priority to JP2018527739A priority patent/JP6979950B2/ja
Priority to MX2018006582A priority patent/MX2018006582A/es
Priority to KR1020187018244A priority patent/KR102208317B1/ko
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP16806285.9A priority patent/EP3383918A1/fr
Priority to BR112018010102-8A priority patent/BR112018010102A2/pt
Priority to SG11201803676PA priority patent/SG11201803676PA/en
Publication of WO2017093844A1 publication Critical patent/WO2017093844A1/fr
Priority to ZA2018/03205A priority patent/ZA201803205B/en
Priority to PH12018501043A priority patent/PH12018501043A1/en
Priority to CONC2018/0005433A priority patent/CO2018005433A2/es
Priority to IL259651A priority patent/IL259651B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • the present invention relates to site specific HER2 antibody drug conjugates.
  • the present invention further relates to the methods of using such antibody drug conjugates for the treatment of cancer.
  • the receptor family includes four distinct members, including epidermal growth factor receptor (EGFR or ErbB1), HER2 (ErbB2 or p185), HER3 (ErbB3) and HER4 (ErbB4 or tyro2).
  • EGFR epidermal growth factor receptor
  • HER2 ErbB2 or p185
  • HER3 ErbB3
  • HER4 ErbB4 or tyro2
  • HER2 was originally identified as the product of the transforming gene from neuroblastomas of chemically treated rats. HER2 overexpression has been validated as tumorigenic both in vitro (Di Fiore et al., 1987, Science 237(4811): 178-82; Hudziak et al., 1987, PNAS 84(20):7159-63; Chazin et al., 1992, Oncogene 7(9): 1859-66) and in animal models (Guy et al., 1992, PNAS 89(22): 10578-82).
  • Amplification of the gene encoding HER2 with consequent overexpression of the receptor occurs in breast and ovarian cancers and correlates with a poor prognosis (Slamon et al., 1987, Science 235(4785): 177-82; Slamon et al., 1989, Science 244:707-12; Anbazhagan et al., 1991 , Annals Oncology 2(1):47-53; Andrulis et al., 1998, J Clinical Oncology 16(4): 1340-9).
  • HER2 (frequently but not necessarily due to gene amplification) has also been observed in other tumor types including gastric, endometrial, non-small cell lung cancer, colon, pancreatic, bladder, kidney, prostate and cervical (Scholl et al., 2001 , Annals Oncology 12 (Suppl. 1):S81-7; Menard et al., 2001 , Ann Oncol 12(Suppl 1):S15-9; Martin et al., 2014, Future Oncology 10: 1469-86).
  • Herceptin ® (trastuzumab) is a humanized monoclonal antibody that binds to the extracellular domain of HER2 (Carter et al. 1992, PNAS 89:4285-9 and US Patent No. 5,821 ,337). Herceptin ® received marketing approval from the Food and Drug
  • Herceptin ® is a breakthrough in treating patients with HER2-overexpressing breast cancers that have received extensive prior anti-cancer therapy, segments of patients in this population fail to respond, respond only poorly or become resistant to Herceptin ® treatment.
  • Kadcyla ® (trastuzumab-DM1 or T-DM1) is an antibody drug conjugate consisting of trastuzumab conjugated to the maytansinoid agent DM1 via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate) (Lewis et al., 2008,
  • Kadcyla ® received marketing approval from the Food and Drug
  • the present invention provides site specific HER2 antibody drug conjugates (ADCs) and their use in treatment of HER2-expressing cancers.
  • ADCs enable targeted delivery of therapeutics to cancer cells and offer potential for more selective therapy while reducing known off-target toxicities.
  • a site specific HER2 ADC of the invention is generally of the formula: Ab-(L-D), wherein Ab is an antibody, or antigen-binding fragment thereof, that binds to HER2; and L-D is a linker-drug moiety, wherein L is a linker, and D is a drug.
  • the antibody (Ab) of the ADCs of the invention can be any HER2-binding antibody.
  • the Ab binds to the same epitope on HER2 as trastuzumab (Herceptin ® ).
  • the Ab has the same heavy chain and light chain CDRs as trastuzumab.
  • the Ab has the same heavy chain variable region (VH) and the same light chain variable region (V_) as trastuzumab.
  • the HER2 ADCs of the present invention are conjugated to the drug in a site specific manner.
  • the antibody must be derivatized to provide for either a reactive cysteine residue engineered at one or more specific sites or an acyl donor glutamine residue (either engineered at one or more specific sites or in an attached peptide tag).
  • Such modifications should be at sites that do not disrupt the antigen binding capability of the antibody.
  • the one or more modifications are made in the constant region of the heavy and/or light chains of the antibody.
  • the site specific HER2 ADCs can use antibodies comprising heavy chain variable region CDRs and light chain variable region CDRs of trastuzumab (V H CDRs of SEQ ID NOs:2-4 and V L CDRs of SEQ ID NOs:8-10) and any combination of heavy and light chain constant regions disclosed in Table 1 with the proviso that when the heavy chain constant region is SEQ ID NO:5 then the light chain constant region is not SEQ ID NO: 11.
  • the heavy chain constant region can be selected from any of SEQ ID NOs:17, 5, 13, 21 , 23, 25, 27, 29, 31 , 33, 35, 37 or 39 while the light chain constant region can be selected from any of SEQ ID NOs:41 , 11 or 43 providing that the combination is not SEQ ID NO:5 and SEQ ID NO:1 1.
  • the antibody used to make the site specific HER2 ADC comprises a VH domain with CDRs of SEQ ID NOs:2-4 and a VL domain with CDRs of SEQ ID NOs:8-10 attached to a heavy chain constant region of SEQ ID NO: 17 and a light chain constant region of SEQ ID NO:41.
  • the antibody used to make the site specific HER2 ADC comprises a VH domain with CDRs of SEQ ID NOs:2-4 and a V L domain with CDRs of SEQ ID NOs:8-10 attached to a heavy chain constant region of SEQ ID NO: 13 and a light chain constant region of SEQ ID NO:43.
  • the ADCs of the invention can use antibodies comprising of any combination of heavy and light chains disclosed in Table 1 with the proviso that if the heavy chain is SEQ ID NO:6 then the light chain is not SEQ ID NO: 12.
  • the heavy chain can be selected from any of SEQ ID NOs: 18, 6, 14, 22, 24, 26, 28, 30, 32, 34, 36, 38 or 40 while the light chain can be selected from any of SEQ ID NOs: 42, 12 or 44 providing that the combination is not SEQ ID NO:6 and SEQ ID NO: 12.
  • the ADCs of the invention can use an antibody comprising a heavy chain of SEQ ID NO: 18 and a light chain of SEQ ID NO:42. In another specific embodiment, the ADCs of the invention can use an antibody comprising a heavy chain of SEQ ID NO: 14 and a light chain of SEQ ID NO:44.
  • Any of the site specific HER2 ADCs disclosed herein can be prepared with a drug (D) that is a therapeutic agent useful for treating cancer.
  • D a drug that is a therapeutic agent useful for treating cancer.
  • the therapeutic agent is an anti-mitotic agent.
  • the anti-mitotic agent drug component in the ADCs of the invention is an auristatin (e.g., 0101 , 8261 , 6121 , 8254, 6780 and 0131).
  • auristatin e.g., 0101 , 8261 , 6121 , 8254, 6780 and 0131.
  • the auristatin drug component in the ADCs of the invention is 2- methylalanyl-N-[(3R,4S,5S)-3-methoxy-1- ⁇ (2S)-2-[(1 R,2R)-1-methoxy-2-methyl-3-oxo-3- ⁇ [(1 S)-2-phenyl-1-(1 ,3-thiazol-2-yl)ethyl]amino ⁇ propyl]pyrrolidin-1-yl ⁇ -5-methyl-1- oxoheptan-4-yl]-N-methyl-L-valinamide (also known as 0101).
  • the drug component of the ADCs of the invention is membrane permeable.
  • Any of the site specific HER2 ADCs disclosed herein can be prepared with a linker (L) that is cleavable or non-cleavable.
  • the linker is cleavable.
  • Cleavable linkers include, but are not limited to, vc, AcLysvc and m(H20)c-vc. More preferably, the linker is vc or AcLysvc.
  • site specific HER2 ADC of the formula Ab- (L-D) comprises (a) an antibody, Ab, comprising a heavy chain of SEQ ID NO:18 and a light chain of SEQ ID NO:42; and (b) a linker-drug moiety, L-D, wherein L is a linker, and D is a drug, wherein the linker is vc and wherein the drug is 0101.
  • site specific HER2 ADC of the formula Ab-(L-D) comprises (a) an antibody, Ab, comprising a heavy chain of SEQ ID NO:14 and a light chain of SEQ ID NO:44; and (b) a linker-drug moiety, L-D, wherein L is a linker, and D is a drug, wherein the linker is AcLysvc and wherein the drug is 0101.
  • Another aspect of the invention includes methods of making, methods of preparing, methods of synthesis, methods of conjugation and methods of purification of the antibody drug conjugates disclosed herein and the intermediates for the
  • compositions comprising a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acid sequence having a site specific amino acids
  • HER2 ADC disclosed herein and a pharmaceutically acceptable carrier.
  • Nucleic acids encoding the antibody portion of the site specific HER2 ADCs are contemplated by the invention. Additional vectors and host cells comprising the nucleic acids are also contemplate by the invention.
  • the present invention also provides method of use of the site specific HER2 ADCs in the treatment of HER2-expressing cancers.
  • HER2-expressing cancer to be treated with the site specific HER2 ADCs of the invention can express HER2 at a high, moderate or low level.
  • the cancer to be treated is resistant to, refractory to and/or relapsed from treatment with trastuzumab and/or trastuzumab emtansine (T-DM1) either of which alone or in combination with a taxane.
  • Cancers to be treated include, but are not limited to, breast cancer, ovarian cancer, lung cancer, gastric cancer, esophageal cancer, colorectal cancer, urothelial cancer, pancreatic cancer, salivary gland cancer and brain cancer or metastases of the aforementioned cancers.
  • the breast cancer is estrogen receptor and progesterone receptor negative breast cancer or triple negative breast cancer (TNBC).
  • the lung cancer is non-small cell lung cancer (NSCLC).
  • FIGS. 1A-1 B depict (A) T(kK183C+K290C)-vc0101 ADC and (B) T(LCQ05+K222R)- Acl_ysvc0101 ADC.
  • Each black circle represents a linker/payload that is conjugated to the monoclonal antibody. The structure of one such linker/payload is shown for each ADC. The underlined entity is supplied by the amino acid residue on the antibody through which conjugation occurs.
  • FIGS. 2A-2E depict spectra of selected ADCs from hydrophobic interaction
  • HIC chromatography
  • FIGS. 3A-3B depict graphs of ADCs binding to HER2.
  • A direct binding to HER2 positive BT474 cells and
  • B competitive binding with PE labelled trastuzumab to BT474 cells.
  • FIG. 4 depicts ADCC activities of trastuzumab derived ADCs.
  • FIG. 5 depicts in vitro cytotoxicity data (IC50) reported in nM payload concentration for a number of trastuzumab derived ADCs on a number of cell lines with different levels of HER2 expression.
  • FIG. 6 depicts in vitro cytotoxicity data (IC50) reported in ng/ml antibody concentration for a number of trastuzumab derived ADCs on a number of cell lines with different levels of HER2 expression.
  • FIGS. 7A-7I depict anti-tumor activity of nine trastuzumab derived ADCs on N87 xenografts with tumor volume was plotted over time.
  • A T(kK183C+K290C)-vc0101 ;
  • B T(kK183C)-vc0101 ;
  • C T(K290C)-vc0101 ;
  • D T(LCQ05+K222R)-AcLysvc0101 ;
  • E T(K290C+K334C)-vc0101 ;
  • F T(K334C+K392C)-vc0101 ;
  • G T(N297Q+K222R)- Acl_ysvc0101 ;
  • H T-vc0101 ;
  • I T-DM 1.
  • N87 gastric cancer cells express high levels of HER2.
  • FIGS. 8A-8E depict anti-tumor activity of six trastuzumab derived ADCs on HCC1954 xenografts with tumor volume plotted over time.
  • A T(LCQ05+K222R)-AcLysvc0101 ;
  • B T(K290C+K334C)-vc0101 ;
  • C T(K334C+K392C)-vc0101 ;
  • D T(N297Q+K222R)- Acl_ysvc0101 ;
  • E T-DM1.
  • HCC1954 breast cancer cells express high levels of HER2.
  • FIGS. 9A-9G depict anti-tumor activity of seven trastuzumab derived ADCs on JIMT-1 xenografts with tumor volume plotted over time.
  • A T(kK183C+K290C)-vc0101 ;
  • B T(LCQ05+K222R)-AcLysvc0101 ;
  • C T(K290C+K334C)-vc0101 ;
  • D T(K334C+K392C)- VC0101 ;
  • E T(N297Q+K222R)-AcLysvc0101 ;
  • F T-vc0101 ;
  • G T-DM1. JIMT-1 breast cancer cells express moderate/low levels of HER2.
  • FIGS. 10A-10D depict anti-tumor activity of five trastuzumab derived ADCs on MDA- MB-361 (DYT2) xenografts with tumor volume plotted over time.
  • A T(LCQ05+K222R)- Acl_ysvc0101 ;
  • B T(N297Q+K222R)-AcLysvc0101 ;
  • C T-vc0101 ;
  • D T-DM1.
  • MDA- MB-361 (DYT2) breast cancer cells express moderate/low levels of HER2.
  • FIGS. 1 1 A-11 E depict anti-tumor activity of five trastuzumab derived ADCs on PDX- 144580 patient derived xenografts with tumor volume plotted over time.
  • FIGS. 12A-12D depict anti-tumor activity of four trastuzumab derived ADCs on PDX- 37622 patient derived xenografts with tumor volume plotted over time.
  • PDX-37622 patient derived cells are a NSCLC PDX model expressing moderate levels of HER2.
  • FIGS. 13A-13B depict immunohistocytochemistry of N87 tumor xenografts treated with either (A) T-DM1 or (B) T-vc0101 and stained for phosphohistone H3 and IgG antibody. Bystander activity is observed with T-vc0101.
  • FIG. 14 depicts in vitro cytotoxicity data (IC50) reported in nM payload concentration and ng/ml antibody concentration for a number of trastuzumab derived ADCs and free payloads on cells made resistant to T-DM1 in vitro (N87-TM1 and N87-TM2) or parental cells sensitive to T-DM1 (N87cells).
  • IC50 in vitro cytotoxicity data reported in nM payload concentration and ng/ml antibody concentration for a number of trastuzumab derived ADCs and free payloads on cells made resistant to T-DM1 in vitro (N87-TM1 and N87-TM2) or parental cells sensitive to T-DM1 (N87cells).
  • FIGS. 15A-15G depict anti-tumor activity of seven trastuzumab derived ADCs on T- DM1 sensitive (N87 cells) and resistant (N87-TM1 and N87-TM2) gastric cancer cells.
  • A T-DM1 ;
  • B T-mc8261 ;
  • C T(297Q+K222R)-AcLysvc0101 ;
  • D T(LCQ05+K222R)- AcLysvc0101 ;
  • E T(K290C+K334C)-vc0101 ;
  • F T(K334C+K392C)-vc0101 ;
  • G G
  • FIGS. 16A-16B depict western blots showing (A) MRP1 drug efflux pump and (B)
  • FIGS. 17A-17B depict HER2 expression and binding to trastuzumab of T-DM1 sensitive (N87 cells) and resistant (N87-TM 1 and N87-TM2) gastric cancer cells.
  • A a western blot showing HER2 protein expression and
  • B trastuzumab binding to cell surface HER2.
  • FIGS. 18A-18D depict characterization of protein expression levels in T-DM1 sensitive (N87 cells) and resistant (N87-TM 1 and N87-TM2) gastric cancer cells.
  • A protein expression level changes in 523 proteins
  • B western blots showing protein expression of IGF2R, LAMP1 and CTSB
  • C western blot showing protein expression of CAV1
  • D IHC of CAV1 protein expression in tumors generated in vivo from implantation of N87 cells (left panel) and N87-TM2 cells (right panel).
  • FIGS. 19A-19C depict sensitivity to trastuzumab and various trastuzumab derived ADCs of tumors generated in vivo from implantation of (A) T-DM1 sensitive N87 parental cells; (B) T-DM1 resistant N87-TM1 cells; (C) T-DM1 resistant N87-TM2 cells.
  • FIGS. 20A-20F depict sensitivity to trastuzumab and various trastuzumab derived ADCs of tumors generated in vivo from implantation of T-DM1 sensitive N87 parental cells and T-DM1 resistant N87-TM2 or N87-TM1 cells.
  • N87 tumor size was plotted over time in the presence of trastuzumab or two trastuzumab derived ADCs;
  • N87- TM2 tumor size was plotted over time in the presence of trastuzumab or two trastuzumab derived ADCs.
  • FIGS. 21A-21 E depict generation and characterization of T-DM1 resistant cells generated in vivo.
  • N87 gastric cancer cells were initially sensitive to T-DM1 when implanted in vivo.
  • B Over time, the implanted N87 cells became resistant to T-DM1 but remained sensitive to (C) T-vc0101 , (D) T(N297Q+K222R)-AcLysvc0101 and (E) T(kK183+K290C)-vc0101.
  • FIGS. 22A-22D depict in vitro cytotoxicity of four trastuzumab derived ADCs on T-DM1 resistant cells (N87-TDM) generated in vivo compared to T-DM1 sensitive parental N87 cells with tumor volume plotted over time.
  • A T-DM1 ;
  • B T(kK183+K290C)-vc0101 ;
  • C T(LCQ05+K222R)-AcLysvc0101 ;
  • D T(N297Q+K222R)-AcLysvc0101.
  • FIGS. 23A-23B depict HER2 protein expression levels on T-DM1 resistant cells (N87- TDM 1 , from mice 2, 17 and 18) generated in vivo compared to T-DM1 sensitive parental N87 cells.
  • A FACS analysis and
  • B western blot analysis. No significant difference in HER2 protein expression was observed.
  • FIGS. 24A-24D depict that T-DM1 resistance in N87-TDM1 (mice 2, 7 and 17) is not due to drug efflux pumps.
  • A a western blot showing MDR1 protein expression.
  • N87-TDM1 resistant cells N87-TDM1
  • T-DM1 sensitive N87 parental cells in the presence of free drug
  • B 0101
  • C doxorubicin
  • D T-DM1.
  • FIGS. 25A-25B depict concentration vs time profiles
  • pharmacokinetics/toxicokinetics of (A) both total Ab and trastuzumab ADC (T-vc0101) or T(kK183C+K290C) site specific ADC after dose administration to cynomolgus monkeys and (B) the ADC analyte of trastuzumab (T-vc0101) or various site specific ADCs after dose administration to cynomolgus monkeys.
  • FIG. 26 depicts relative retention values by hydrophobic interaction chromatography (HIC) vs exposure (AUC) in rats.
  • the X-axis represents Relative Retention Time by HIV; while the Y-axis represents pharmacokinetic dose-normalized exposure in rats ("area under curve", AUC for antibody, from 0 to 336 hours, divided by drug dose of 10 mg/kg).
  • FIG. 27 depicts a toxicity study using T-vc0101 conventional conjugate ADC and T(kK183C+K290C)-vc0101 site specific ADC.
  • T-vc0101 induced severe neutropenia at 5 mg/kg while the T(kK183C+K290C)-vc0101 caused a minimal drop in neutrophil counts at 9 mg/kg.
  • FIGS. 28A-28C depict the crystal structure of (A) T(K290C+K334C)-vc0101 ; (B)
  • FIG. 29 depicts in vivo efficacy on a xenograft model using the N87 cell line. All ADCs tested showed efficacy at 3mpk.
  • FIG. 30 depicts anti-tumor activity of trastuzumab and two trastuzumab derived ADCs on PDX-GA0044 patient derived xenografts with tumor volume plotted over time.
  • PDX-GA0044 patient derived cells are a Gastric PDX model expressing moderate levels of HER2. DETAILED DESCRIPTION OF THE INVENTION
  • the present invention provides site specific HER2 antibody drug conjugates (ADCs), processes for preparing the conjugates using HER2 antibodies, linkers, and drug payloads and nucleic acids encoding the antibodies used in making the ADCs.
  • ADCs of the invention are useful for the preparation and manufacture of compositions, such as medicaments, that can be used in the treatment of HER2- expressing cancers.
  • ADCs consist of an antibody component conjugated to a drug payload through the use of a linker.
  • Conventional conjugation strategies for ADCs rely on randomly conjugating the drug payload to the antibody through lysines or cysteines that are endogenously on the antibody heavy and/or light chain. Accordingly, such ADCs are a heterogeneous mixture of species showing different drug:antibody ratios (DAR).
  • the ADCs disclosed herein are site specific ADCs that conjugate the drug payload to the antibody at particular engineered residues on the antibody heavy and/or light chain.
  • the site specific ADCs are a homogeneous population of ADCs comprised of a species with a defined drug:antibody ratio (DAR).
  • ADCs of the invention demonstrate uniform stoichiometry resulting in improved pharmacokinetics, biodistribution and safety profile of the conjugate.
  • ADCs of the invention include antibodies of the invention conjugated to one or more linker/payload moieties.
  • the present invention provides antibody drug conjugates of the formula Ab-(L- D), wherein (a) Ab is an antibody, or antigen-binding fragment thereof, that binds to HER2, and (b) L-D is a linker-drug moiety, wherein L is a linker, and D is a drug.
  • antibody drug conjugates of the formula Ab-(L-D) p wherein (a) Ab is an antibody, or antigen-binding fragment thereof, that binds to HER2, (b) L-D is a linker-drug moiety, wherein L is a linker, and D is a drug and (c) p is the number of linker/drug moieties are attached to the antibody.
  • Ab is an antibody, or antigen-binding fragment thereof, that binds to HER2
  • L-D is a linker-drug moiety, wherein L is a linker, and D is a drug
  • p is the number of linker/drug moieties are attached to the antibody.
  • p is a whole number due to the homogeneous nature of the ADC.
  • p is 4.
  • p is 3.
  • p is 2.
  • p is 1.
  • p is greater than 4.
  • HER2 refers to a transmembrane tyrosine kinase receptor that belongs to the EGFR family. HER2 is also known as ErbB2, p185 and CD340. This family of receptors includes four members (EGFR/HER1 , HER2, HER3 and HER4) that function by stimulating growth factor signaling pathways such as the PI3K-AKT-mTOR pathway. Amplification and/or overexpression of HER2 is associated with multiple human malignancies. The wild type human HER2 protein is described, for example, in Semba et al., 1985, PNAS 82:6497-6501 and Yamamoto et al., 1986, Nature 319:230-4 and Genbank Accession Number X03363.
  • Antibody refers to an immunoglobulin molecule capable of recognizing and binding to a specific target or antigen, such as a
  • polypeptide through at least one antigen recognition site located in the variable region of the immunoglobulin molecule.
  • the term can encompass any type of antibody, including but not limited to monoclonal antibodies, antigen-binding fragments of intact antibodies that retain the ability to specifically bind to a given antigen (i.e., Fab, Fab', F(ab')2, Fd, Fv, Fc, etc.) and mutants thereof.
  • Native or naturally occurring antibodies, and native immunoglobulins are typically heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains.
  • VH variable domain
  • Each light chain has a variable domain at one end (V L ) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.
  • V L variable domain at one end
  • variable domain refers to the fact that certain portions of the variable domains differ extensively in sequence among antibodies.
  • the antibody used in the present invention specifically binds to HER2.
  • the HER2 antibody binds to the same epitope on HER2 as trastuzumab (Herceptin®).
  • the HER2 antibody has the same variable region CDRs as trastuzumab (Herceptin®).
  • the HER2 antibody has the same variable regions (i.e. , VH and VL) as trastuzumab (Herceptin®).
  • Linker (L) describes the direct or indirect linkage of the antibody to the drug payload. Attachment of a linker to an antibody can be accomplished in a variety of ways, such as through surface lysines, reductive-coupling to oxidized carbohydrates, cysteine residues liberated by reducing interchain disulfide linkages, reactive cysteine residues engineered at specific sites, and acyl donor glutamine-containing tag or an endogenous glutamine made reactive by polypeptide engineering in the presence of transglutaminase and an amine.
  • the present invention uses site specific methods to link the antibody to the drug payload. In one embodiment, conjugation occurs through cysteine residues that have been engineered into the antibody constant region.
  • conjugation occurs through acyl donor glutamine residues that have either been a) added to the antibody constant region via a peptide tag, b) engineered into the antibody constant region or c) made accessible/reactive by engineering surrounding residues.
  • Linkers can be cleavable (i.e., susceptible to cleavage under intracellular conditions) or non-cleavable. In some embodiments, the linker is a cleavable linker.
  • drug (D) refers to any therapeutic agent useful in treating cancer.
  • the drug has biological or detectable activity, for example, cytotoxic agents, chemotherapeutic agents, cytostatic agents, and immunomodulatory agents.
  • therapeutic agents have a cytotoxic effect on tumors including the depletion, elimination and/or the killing of tumor cells.
  • drug, payload, and drug payload are used interchangeably.
  • the drug is an antimitotic agent.
  • the drug is an auristatin.
  • the drug is 2-methylalanyl-N-[(3R,4S,5S)-3-methoxy-1- ⁇ (2S)-2- [(1 R,2R)-1-methoxy-2-methyl-3-oxo-3- ⁇ [(1S)-2-phenyl-1-(1 ,3-thiazol-2- yl)ethyl]amino ⁇ propyl]pyrrolidin-1-yl ⁇ -5- methyl- 1-oxoheptan-4-yl]-N-methyl-L-valinamide (also known as 0101).
  • the drug is preferably membrane permeable.
  • L-D refers to a linker-drug moiety resulting from a drug (D) linked to a linker (L).
  • the antibody can be any antibody that specifically binds to the extracellular domain of HER2.
  • the antibody used to make the ADC binds to the same epitope of HER2 as trastuzumab and/or competes with trastuzumab for HER2 binding.
  • the antibody used to make the ADC has the same heavy chain variable region CDRs and light chain variable region CDRs as trastuzumab.
  • the antibody used to make the ADC has the same heavy chain variable region and light chain variable region as trastuzumab.
  • Compet means that a first antibody, or an antigen-binding fragment thereof, binds to an epitope in a manner sufficiently similar to the binding of a second antibody, or an antigen-binding fragment thereof, such that the result of binding of the first antibody with its cognate epitope is detectably decreased in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody.
  • the alternative, where the binding of the second antibody to its epitope is also detectably decreased in the presence of the first antibody can, but need not be the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope.
  • each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to "cross- compete" with each other for binding of their respective epitope(s).
  • Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof), the skilled artisan would appreciate, based upon the teachings provided herein, that such competing and/or cross-competing antibodies are encompassed and can be useful for the methods disclosed herein.
  • Trastuzumab (trade name Herceptin ® ) is a humanized monoclonal antibody that binds to the extracellular domain of HER2.
  • the amino acid sequences of its variable domains are disclosed in US Patent No. 5,821 ,337 (V H is SEQ ID NO:42 and V L is SEQ ID NO:41 of US Patent No. 5,821 ,337) as well as in Table 1 infra (SEQ ID NOs: 1 and 7, respectively).
  • the amino acid sequences of the heavy chain variable region CDRs are SEQ ID NOs:2-4 while the amino acid sequences of the light chain CDRs are SEQ ID NOs:6-10 (Table 1 infra).
  • the amino acid sequences of the complete heavy and light chains are SEQ ID NOs:6 and 12, respectively (Table 1 infra).
  • T-DM1 (trade name Kadcyla ® ) is an antibody drug conjugate consisting of trastuzumab conjugated to the maytansinoid agent DM1 via the stable thioether linker MCC (4-[N-maleimidomethyl] cyclohexane-1-carboxylate) (US Patent No. 8,337,856).
  • the antibody component of this ADC is identical to trastuzumab.
  • Payload conjugation to trastuzumab is accomplished using conventional conjugation (rather than site specific) techniques such that the ADC is a heterogeneous population of species with different amounts of DM1 conjugated to each one.
  • the DM1 payload inhibits cell proliferation by inhibiting the formation of microtubules during mitosis through inhibition of tubulin polymerization (Remillard et al., 1975, Science 189: 1002-5).
  • Kadcyla ® is approved for the treatment of HER2 positive metastatic breast cancer in patients who had been previously treated with Herceptin and a taxane drug and became Herceptin refractory.
  • T-DM1 used in the experiments described in the Examples Section was made internally using publically available information.
  • the ADCs of the present invention are conjugated to the payload in a site specific manner.
  • the antibody must be derivatized to provide for either a reactive cysteine residue engineered at one or more specific sites, an acyl donor glutamine-containing tag or an endogenous glutamine made reactive by polypeptide engineering in the presence of transglutaminase and an amine.
  • Amino acid modifications can be made by any method known in the art and many such methods are well known and routine for the skilled artisan. For example, but not by way of limitation, amino acid substitutions, deletions and insertions may be accomplished using any well-known PCR-based technique. Amino acid substitutions may be made by site-directed mutagenesis (see, for example, Zoller and Smith, 1982, Nucl. Acids Res. 10:6487-6500; and Kunkel, 1985, PNAS 82:488).
  • the one or more modifications are made in the constant region of the heavy and/or light chains.
  • constant region of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination.
  • the constant regions of the antibodies used to make the ADCs of the invention may be derived from constant regions of any one of IgA, IgD, IgE, IgG, IgM, or any isotypes thereof as well as subclasses and mutated versions thereof.
  • the constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as Fc receptor (FcR) binding, participation of the antibody in antibody-dependent cellular toxicity (ADCC),
  • Fc region is used to define a C-terminal region of an immunoglobulin heavy chain.
  • the "Fc region” may be a native sequence Fc region or a variant Fc region.
  • the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
  • the numbering of the residues in the Fc region is that of the EU Index of Kabat (Kabat et al., Sequences of Proteins of
  • the Fc region of an immunoglobulin generally has two constant regions, CH2 and CH3.
  • CLK has known polymorphic loci CI_K-V/A 45 and CLK-L/V 83 (using the Kabat numbering system as set forth in Kabat et al. (1991 , NIH Publication 91 - 3242, National Technical Information Service, Springfield, VA), so all Kappa and Lambda positions are numbered according to the Kabat system.) thus allowing for
  • Polypeptides, antibodies and ADCs of the invention can have antibody components with any of these light chain constant regions.
  • amino acid residues in the human IgG heavy constant domain of an antibody are numbered according the EU index of
  • the Fc domain comprises from about amino acid residue 236 to about 447 of the human lgG1 constant domain. Correspondence between C numberings can be found, e.g., at IGMT database. Amino acid residues of the light chain constant domain are numbered according to Kabat et al., 1991. Numbering of antibody constant domain amino acid residues is also shown in International Patent Publication No. WO 2013/093809. The only exception to the use of EU index of Kabat in IgG heavy constant domain is residue A114 described in the examples. A114 refers to Kabat numbering, and the
  • Nucleic acids encoding the heavy and light chains of the antibodies used to make the ADCs of the invention can be cloned into a vector for expression or propagation.
  • the sequence encoding the antibody of interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for future use.
  • the term "vector” refers to a construct which is capable of delivering, and preferably, expressing, one or more gene(s) or sequence(s) of interest in a host cell.
  • vectors include, but are not limited to, viral vectors, naked DNA or RNA expression vectors, plasmid, cosmid or phage vectors, DNA or RNA expression vectors associated with cationic condensing agents, DNA or RNA expression vectors encapsulated in liposomes, and certain eukaryotic cells, such as producer cells.
  • host cell includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts.
  • Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
  • a host cell includes cells transfected in vivo with a nucleic acids or vectors of this invention. Table 1 provides the amino acid (protein) sequences and associated nucleic acid
  • the antibody heavy chains and light chains shown in Table 1 have the trastuzumab heavy chain variable region (V H ) and light chain variable region (V L ).
  • the heavy chain constant region and light chain constant region are derivatized from trastuzumab and contain on or more modification to allow for site specific conjugation when making the ADCs of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des conjugués anticorps-médicaments anti-HER2 spécifiques de sites et des procédés de préparation et d'utilisation de ces conjugués.
PCT/IB2016/057017 2015-11-30 2016-11-22 Conjugués anticorps-médicaments anti-her2 spécifiques de sites WO2017093844A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SG11201803676PA SG11201803676PA (en) 2015-11-30 2016-11-22 Site specific her2 antibody drug conjugates
KR1020187018244A KR102208317B1 (ko) 2015-11-30 2016-11-22 부위 특이적 her2 항체 약물 접합체
RU2018119683A RU2745565C2 (ru) 2015-11-30 2016-11-22 Сайт-специфические конъюгаты антитела к her2 и лекарственного средства
CN201680072749.4A CN108473591B (zh) 2015-11-30 2016-11-22 位点特异性her2抗体药物缀合物
EP16806285.9A EP3383918A1 (fr) 2015-11-30 2016-11-22 Conjugués anticorps-médicaments anti-her2 spécifiques de sites
MX2018006582A MX2018006582A (es) 2015-11-30 2016-11-22 Conjugados de farmaco de anticuerpo her2 especificos de sitio.
KR1020207030005A KR102312149B1 (ko) 2015-11-30 2016-11-22 부위 특이적 her2 항체 약물 접합체
AU2016363373A AU2016363373A1 (en) 2015-11-30 2016-11-22 Site specific HER2 antibody drug conjugates
JP2018527739A JP6979950B2 (ja) 2015-11-30 2016-11-22 部位特異的ｈｅｒ２抗体薬物コンジュゲート
BR112018010102-8A BR112018010102A2 (pt) 2015-11-30 2016-11-22 conjugados farmacêuticos de anticorpos sítio-específicos para her2
ZA2018/03205A ZA201803205B (en) 2015-11-30 2018-05-15 Site specific her2 antibody drug conjugates
PH12018501043A PH12018501043A1 (en) 2015-11-30 2018-05-16 Site specific her2 antibody drug conjugates
CONC2018/0005433A CO2018005433A2 (es) 2015-11-30 2018-05-24 Conjugados de fármaco de anticuerpo her2 específicos de sitio
IL259651A IL259651B2 (en) 2015-11-30 2018-05-28 Conjugations between an antibody to a specific her2 site and a drug

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562260854P 2015-11-30 2015-11-30
US62/260,854 2015-11-30
US201662289727P 2016-02-01 2016-02-01
US201662289744P 2016-02-01 2016-02-01
US62/289,727 2016-02-01
US62/289,744 2016-02-01
US201662409105P 2016-10-17 2016-10-17
US62/409,105 2016-10-17

Publications (1)

Publication Number Publication Date
WO2017093844A1 true WO2017093844A1 (fr) 2017-06-08

Family

ID=57485830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/057017 WO2017093844A1 (fr) 2015-11-30 2016-11-22 Conjugués anticorps-médicaments anti-her2 spécifiques de sites

Country Status (17)

Country Link
US (2) US10689458B2 (fr)
EP (1) EP3383918A1 (fr)
JP (1) JP6979950B2 (fr)
KR (2) KR102208317B1 (fr)
CN (1) CN108473591B (fr)
AU (1) AU2016363373A1 (fr)
BR (1) BR112018010102A2 (fr)
CA (1) CA2949032A1 (fr)
CO (1) CO2018005433A2 (fr)
IL (1) IL259651B2 (fr)
MX (1) MX2018006582A (fr)
PH (1) PH12018501043A1 (fr)
RU (1) RU2745565C2 (fr)
SG (2) SG11201803676PA (fr)
TW (3) TWI778491B (fr)
WO (1) WO2017093844A1 (fr)
ZA (1) ZA201803205B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020128893A1 (fr) 2018-12-21 2020-06-25 Pfizer Inc. Traitements combinés de cancer comprenant un agoniste de tlr
WO2021086981A1 (fr) * 2019-10-29 2021-05-06 Cspc Dophen Corporation Compositions et méthodes de traitement du cancer au moyen d'un conjugué anticorps-médicament anti-her2
WO2021124210A1 (fr) 2019-12-20 2021-06-24 Pfizer Inc. Traitement avec des conjugués anticorps-médicament her2 spécifiques à un site
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2022029591A1 (fr) 2020-08-04 2022-02-10 Pfizer Inc. Traitement avec des conjugués anticorps-médicament her2 spécifiques à un site
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US11833216B2 (en) 2016-10-17 2023-12-05 Pfizer Inc. Anti-EDB antibodies and antibody-drug conjugates

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021143741A1 (fr) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 Conjugué polypeptide-médicament de ciblage et utilisation de celui-ci
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
IL302017A (en) 2020-10-25 2023-06-01 Araris Biotech Ag Means and methods for creating antibody-linker conjugates
JP2024506708A (ja) * 2021-02-18 2024-02-14 レメゲン シーオー．，エルティーディー． 特定の乳癌の治療におけるｈｅｒ２を標的とする抗体薬物複合体の使用
AU2022358772A1 (en) * 2021-10-10 2024-05-02 Elixiron Immunotherapeutics (hong Kong) Limited Method of treating diseases with anti-pd-l1/il-10 fusion proteins
WO2023072934A1 (fr) * 2021-10-25 2023-05-04 Araris Biotech Ag Procédés de production de conjugués anticorps-lieur
AU2023210951A1 (en) * 2022-01-26 2024-07-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her2/trop2 antibodies and uses thereof
WO2024162772A1 (fr) * 2023-02-01 2024-08-08 주식회사 에이티지씨 Conjugués de substances bioactives à persistance in vivo améliorée

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5648095A (en) 1991-08-01 1997-07-15 Danbiosyst Uk Limited Preparation of microparticles
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO2000053211A2 (fr) 1999-03-09 2000-09-14 University Of Southern California Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6461603B2 (en) 2000-02-28 2002-10-08 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
WO2012059882A2 (fr) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Conjugués de polypeptides obtenus par génie biologique, et procédé de fabrication correspondants au moyen de transglutaminase
US8337856B2 (en) 2000-03-16 2012-12-25 Immunogen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
WO2013072813A2 (fr) 2011-11-17 2013-05-23 Pfizer Inc. Peptides cytotoxiques et conjugués anticorps-médicaments de ceux-ci
WO2013093809A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2014072888A1 (fr) * 2012-11-07 2014-05-15 Pfizer Inc. Anticorps anti-récepteur alpha 2 de l'il-13 et conjugués anticorps-médicaments
WO2014124316A2 (fr) * 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
KR20120068807A (ko) 2004-07-22 2012-06-27 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
EP1853294A4 (fr) 2005-03-03 2010-01-27 Covx Technologies Ireland Ltd Composés antiangiogéniques
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
US20090098115A1 (en) * 2006-10-20 2009-04-16 Lisa Michele Crocker Cell lines and animal models of HER2 expressing tumors
KR101622412B1 (ko) 2007-10-19 2016-05-18 제넨테크, 인크. 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
CL2009000062A1 (es) 2008-01-31 2010-05-14 Genentech Inc Anticuerpo humanizado anti cd79b; con modificaciones de cisterna libre; inmunoconjugado que contiene dicho anticuerpo y una droga; polinucleotido que codifica el anticuerpo; vector, celula huesped; composicion farmaceutica y uso de dicha composicion para tratar cancer, preferentemente linfomas.
WO2011005481A1 (fr) 2009-06-22 2011-01-13 Medimmune, Llc Régions fc de synthèse pour une conjugaison spécifique à un site
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US10208129B2 (en) 2010-12-06 2019-02-19 National Research Council Of Canada Antibodies selective for cells presenting ErbB2 at high density
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2854720C (fr) 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Anticorps specifiques de trop-2 et leurs utilisations
EP2844289B1 (fr) 2012-04-30 2019-07-17 MedImmune, LLC Molécules ayant une fonction effectrice réduite et des demi-vies allongées, compositions et utilisations de celles-ci
EA037203B1 (ru) 2012-05-15 2021-02-18 Сиэтл Джинетикс, Инк. Конъюгаты антитело-лекарственное средство с самостабилизирующимися линкерами
WO2014022592A1 (fr) 2012-08-02 2014-02-06 Jn Biosciences Llc Anticorps ou protéines de fusion multimérisés par l'intermédiaire de la mutation d'une cystéine et une pièce de queue μ
US9850313B2 (en) 2012-08-03 2017-12-26 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
CA2887896A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sarl Conjugues anticorps anti-her2 - pyrrolobenzodiazepine
CA2885315C (fr) 2012-10-12 2020-06-23 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
JP6389880B2 (ja) 2013-07-03 2018-09-12 ソウル大学校産学協力団Ｓｅｏｕｌ Ｎａｔｉｏｎａｌ Ｕｎｉｖｅｒｓｉｔｙ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ システインで変形された鶏の抗体およびこれを用いた部位特異的接合
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015038426A1 (fr) 2013-09-13 2015-03-19 Asana Biosciences, Llc Lieurs auto-immolables contenant des dérivés d'acide mandélique, conjugués médicament-ligand pour thérapies ciblées, et leurs utilisations
US9239324B2 (en) 2013-12-06 2016-01-19 Gang Chen Antibody-binding protein-drug conjugate and methods of use
CA2934617A1 (fr) 2013-12-23 2015-07-02 Bayer Pharma Aktiengesellschaft Conjugues de liant (conjugue anticorps-medicament) comprenant des inhibiteurs de la proteine kinesine du fuseau
DK3099692T5 (da) 2014-01-27 2020-03-16 Pfizer Bifunktionelle cytotoksiske midler
KR20240042540A (ko) * 2014-02-28 2024-04-02 메뤼스 엔.페. ErbB-2와 ErbB-3에 결합하는 항체
BR112016022910A2 (pt) 2014-04-11 2017-10-17 Medimmune Llc anticorpos contra her2 biespecíficos
WO2015187428A1 (fr) * 2014-06-06 2015-12-10 Redwood Bioscience, Inc. Conjugués anticorps anti-her2-maytansine et méthodes d'utilisation de ceux-ci
RU2682645C1 (ru) 2015-03-20 2019-03-20 Пфайзер Инк. Бифункциональные цитотоксические агенты, содержащие CTI фармакофор
TWI637966B (zh) 2015-11-30 2018-10-11 輝瑞股份有限公司 用於部位專一性接合之抗體和抗體片段

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5648095A (en) 1991-08-01 1997-07-15 Danbiosyst Uk Limited Preparation of microparticles
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO2000053211A2 (fr) 1999-03-09 2000-09-14 University Of Southern California Methode de stimulation de la proliferation de myocytes et de la reparation des tissus myocardiques
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6461603B2 (en) 2000-02-28 2002-10-08 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US8337856B2 (en) 2000-03-16 2012-12-25 Immunogen, Inc. Methods of treatment using anti-ERBB antibody-maytansinoid conjugates
WO2012059882A2 (fr) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Conjugués de polypeptides obtenus par génie biologique, et procédé de fabrication correspondants au moyen de transglutaminase
WO2013072813A2 (fr) 2011-11-17 2013-05-23 Pfizer Inc. Peptides cytotoxiques et conjugués anticorps-médicaments de ceux-ci
WO2013093809A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2014072888A1 (fr) * 2012-11-07 2014-05-15 Pfizer Inc. Anticorps anti-récepteur alpha 2 de l'il-13 et conjugués anticorps-médicaments
WO2014124316A2 (fr) * 2013-02-08 2014-08-14 Irm Llc Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
"Remington, The Science and Practice of Pharmacy 20th Ed.", 2000, MACK PUBLISHING
"Remington, The Science and Practice of Pharmacy 21st Ed.", 2005, MACK PUBLISHING
ANBAZHAGAN ET AL., ANNALS ONCOLOGY, vol. 2, no. 1, 1991, pages 47 - 53
ANDRULIS ET AL., J CLINICAL ONCOLOGY, vol. 16, no. 4, 1998, pages 1340 - 9
BURRIS ET AL., J CLINICAL ONCOLOGY, vol. 29, no. 4, 2011, pages 398 - 405
BURTON ET AL., MOLEC. IMMUNOL., vol. 22, 1985, pages 161 - 206
CARTER ET AL., PNAS, vol. 89, 1992, pages 4285 - 9
CHARI ET AL., CANCER RES, vol. 52, 1992, pages 127 - 31
CHAZIN ET AL., ONCOGENE, vol. 7, no. 9, 1992, pages 1859 - 66
DI FIORE ET AL., SCIENCE, vol. 237, no. 4811, 1987, pages 178 - 82
EDELMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 63, no. 1, 1969, pages 78 - 85
EPPSTEIN ET AL., PNAS, vol. 82, 1985, pages 3688 - 92
FUJIMOTO-OUCHI ET AL., CANCER CHEMOTHER PHARMACOL, vol. 59, no. 6, 2007, pages 795 - 805
GANCBERG ET AL., BREAST CANCER RES TREAT., vol. 74, 2002, pages 113 - 20
GUY ET AL., PNAS, vol. 89, no. 22, 1992, pages 10578 - 82
HUDZIAK ET AL., PNAS, vol. 84, no. 20, 1987, pages 7159 - 63
HWANG ET AL., PNAS, vol. 77, 1908, pages 4030 - 4
JACOBS ET AL., J CLINICAL ONCOLOGY, vol. 17, no. 7, 1999, pages 1974 - 82
JUNUTULA ET AL., NATURE BIOTECHNOLOGY, vol. 26, 2008, pages 925 - 932
K. E. HOOVER: "Remington: The Science and practice of Pharmacy 21st Ed.,", 2005, LIPPINCOTT WILLIAMS AND WILKINS
KABAT ET AL.: "Sequences of Proteins of Immunological Interest, 5th Ed.", 1991, NATIONAL INSTITUTES OF HEALTH
KIM ET AL., BIOCONJ CHEM, vol. 25, no. 7, 2014, pages 1223 - 32
KOVTUN ET AL., CANCER RES, vol. 66, 2006, pages 3214 - 21
KROP ET AL., J CLIN ONCOL., vol. 28, 2010, pages 2698 - 2704
KUNKEL, PNAS, vol. 82, 1985, pages 488
LEWIS ET AL., CANCER RES., vol. 68, 2008, pages 9280 - 90
LYONS A ET AL: "Site-specific attachment to recombinant antibodies via introduced surface cysteine residues", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 3, no. 8, 1 January 1990 (1990-01-01), pages 703 - 708, XP001000052, ISSN: 0269-2139 *
MARTIN ET AL., FUTURE ONCOL., vol. 10, no. 8, 2014, pages 1469 - 86
MARTIN ET AL., FUTURE ONCOLOGY, vol. 10, 2014, pages 1469 - 86
MENARD ET AL., ANN ONCOL, vol. 12, no. 1, 2001, pages S15 - 9
OWENS ET AL., CLIN BREAST CANCER., vol. 5, 2004, pages 63 - 69
PAWEL-RAMMINGEN ET AL., EMBO J., vol. 21, 2002, pages 1607
PRESS ET AL., CLIN CANCER RES., vol. 11, 2005, pages 6598 - 6607
REMILLARD ET AL., SCIENCE, vol. 189, 1975, pages 1002 - 5
SANDRINE BÉRANGER ET AL: "IMGT Scientific chart: Correspondence between the IM GT unique numbering for C-DOM AIN, the IM GT exon numbering, the Eu and Kabat numberings: Human IGHG", 17 May 2001 (2001-05-17), XP055297333, Retrieved from the Internet <URL:http://www.imgt.org/IMGTScientificChart/Numbering/Hu_IGHGnber.html> [retrieved on 20160824] *
SAUTER ET AL., J CLIN ONCOL., vol. 27, 2009, pages 1323 - 33
SCHOLL ET AL., ANNALS ONCOLOGY, vol. 12, no. 1, 2001, pages S81 - 7
SEMBA ET AL., PNAS, vol. 82, 1985, pages 6497 - 6501
SLAMON ET AL., SCIENCE, vol. 235, no. 4785, 1987, pages 177 - 82
SLAMON ET AL., SCIENCE, vol. 244, 1989, pages 707 - 12
THOMAS; COLEY, CANCER CONTROL, vol. 10, no. 2, 2003, pages 159 - 165
VOGEL ET AL., J CLINICAL ONCOLOGY, vol. 20, no. 3, 2002, pages 719 - 726
VOYNOV VLADIMIR ET AL: "Design and application of antibody cysteine variants", BIOCONJUGATE CHEMISTRY,, vol. 21, no. 2, 17 February 2010 (2010-02-17), pages 385 - 392, XP002598497, ISSN: 1043-1802, [retrieved on 20100121], DOI: 10.1021/BC900509S *
WOLFF ET AL., J CLINICAL ONCOLOGY, vol. 25, 2007, pages 118 - 45
WOLFF ET AL., J CLINICAL ONCOLOGY, vol. 31, 2013, pages 3997 - 4014
XIE ET AL., J PHARMACOL EXP THER, vol. 310, 2004, pages 844
YAMAMOTO ET AL., NATURE, vol. 319, 1986, pages 230 - 4
YU ET AL.: "Engineering Hydrophobic Protein-Carbohydrate interactions to fine-tune monoclonal antibodies", JACS, 2013
ZOLLER; SMITH, NUCL. ACIDS RES., vol. 10, 1982, pages 6487 - 6500

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
US11833216B2 (en) 2016-10-17 2023-12-05 Pfizer Inc. Anti-EDB antibodies and antibody-drug conjugates
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2020128893A1 (fr) 2018-12-21 2020-06-25 Pfizer Inc. Traitements combinés de cancer comprenant un agoniste de tlr
WO2021086981A1 (fr) * 2019-10-29 2021-05-06 Cspc Dophen Corporation Compositions et méthodes de traitement du cancer au moyen d'un conjugué anticorps-médicament anti-her2
WO2021124210A1 (fr) 2019-12-20 2021-06-24 Pfizer Inc. Traitement avec des conjugués anticorps-médicament her2 spécifiques à un site
WO2022029591A1 (fr) 2020-08-04 2022-02-10 Pfizer Inc. Traitement avec des conjugués anticorps-médicament her2 spécifiques à un site

Also Published As

Publication number Publication date
EP3383918A1 (fr) 2018-10-10
CN108473591B (zh) 2022-01-28
IL259651B2 (en) 2023-05-01
AU2016363373A1 (en) 2018-05-24
KR20180088435A (ko) 2018-08-03
JP6979950B2 (ja) 2021-12-15
MX2018006582A (es) 2018-12-19
RU2018119683A3 (fr) 2020-01-09
IL259651A (en) 2018-08-30
CO2018005433A2 (es) 2018-05-31
TW202023624A (zh) 2020-07-01
US10689458B2 (en) 2020-06-23
TW202142265A (zh) 2021-11-16
ZA201803205B (en) 2019-02-27
CA2949032A1 (fr) 2017-05-30
IL259651B1 (en) 2023-01-01
KR102312149B1 (ko) 2021-10-12
KR20200122423A (ko) 2020-10-27
US20170151341A1 (en) 2017-06-01
BR112018010102A2 (pt) 2018-11-13
SG10202005102YA (en) 2020-07-29
US20200377615A1 (en) 2020-12-03
TWI726942B (zh) 2021-05-11
TWI727380B (zh) 2021-05-11
RU2018119683A (ru) 2020-01-09
CN108473591A (zh) 2018-08-31
RU2745565C2 (ru) 2021-03-29
TW201731531A (zh) 2017-09-16
JP2018537975A (ja) 2018-12-27
TWI778491B (zh) 2022-09-21
KR102208317B1 (ko) 2021-01-27
SG11201803676PA (en) 2018-06-28
PH12018501043A1 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
US20200377615A1 (en) Site specific her2 antibody drug conjugates
US11279764B2 (en) Antibodies specific for epidermal growth factor receptor variant III and their uses
JP6787890B2 (ja) 抗体−薬物コンジュゲートの選択的製造方法
ES2905315T3 (es) Anticuerpos terapéuticos y sus usos
CA2947148C (fr) Conjugues medicament-anticorps anti-ptk7
JP2021503927A (ja) Ｃｄ４７抗体及びがんを治療するためのその使用
CA2854720C (fr) Anticorps specifiques de trop-2 et leurs utilisations
CN110903395A (zh) 抗体、偶联物及其制备方法和用途
CA2946488A1 (fr) Conjugues anticorps-medicament a charge de medicament elevee
CN113710271A (zh) 抗cd228抗体和抗体-药物缀合物
JP7551750B2 (ja) 抗αｖβ６抗体及び抗体薬物コンジュゲート
CN110575547A (zh) 靶向于tf的抗体-药物偶联物及其制法和用途
JP2020504114A (ja) 抗ｓｅｚ６ｌ２抗体および抗体薬物コンジュゲート
KR20240099430A (ko) 항체 분자 및 접합체
CA3093477A1 (fr) Conjugues anticorps anti-her2 biparatopique-medicament et procedes d&#39;utilisation
CN117999101A (zh) 靶向EGFR的Fc抗原结合片段-药物缀合物
Tabrizi et al. Strategies for Development of Next Generation Antibody-Based Therapeutics

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16806285

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 11201803676P

Country of ref document: SG

Ref document number: 12018501043

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2016363373

Country of ref document: AU

Date of ref document: 20161122

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 001020-2018

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: 259651

Country of ref document: IL

Ref document number: 2018527739

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018010102

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/006582

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20187018244

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016806285

Country of ref document: EP

Ref document number: 2018119683

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2016806285

Country of ref document: EP

Effective date: 20180702

ENP Entry into the national phase

Ref document number: 112018010102

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180518